Shanghai wants to be a stop on the international medical tourism map, and its health officials have opened a pilot that lets city hospitals reshape their care for foreign patients, Citynewsservice reported. The draw it is leading with is traditional Chinese medicine, or TCM, sold as care that is hard to find or dear in the West and much of Southeast Asia. The report put Shanghai Longhua Hospital at the centre of that pitch.
Longhua is a TCM hospital and, the report said, the first in the city to hold Joint Commission International accreditation. It runs its cancer, rehab and anorectal units on a mixed model, pairing Western care with TCM. Much of what follows comes from the hospital’s own account, and the healing and cost figures below could not be checked on their own.
Cancer care
The cancer unit blends standard treatment, surgery, chemotherapy and the rest with TCM drugs and outside methods such as acupuncture and tuina massage, Citynewsservice reported. Dr Liu Lingshuang, who heads the unit, said the aim was to ease side effects and keep patients on their full course. Each plan is built around the patient’s cancer type, age and state, on what the report called the rule of “one person, one prescription”.
The hospital sells speed as much as method. Its foreign wards take patients in within one to two days, the report said, run core tests through a set-aside channel, and settle a joint Chinese-Western plan in three to five days. Patients in Singapore, by contrast, can wait one to two months to be admitted and worked up. Short cycles, the hospital argued, fit visa-free travel and make return trips easier for foreign patients.
The needle-knife
Longhua’s rehab unit leads on acupotomy, a needle-knife method the hospital says it both founded and wrote the city’s standard for. Dr Zhang Ying, who heads the unit, said the therapy was “not available overseas” and worked on long-term joint and nerve pain. The unit also runs other rehab programmes for the nerves, the lungs and the gut, mixing Western steps with TCM.
Cost is the other half of the pitch. A full rehab course in China runs about 1,500 to 2,000 yuan before bed fees, Citynewsservice reported, against fees the hospital put at up to US$2,000 for a single session abroad. Those are the hospital’s own numbers, set inside a sales account of its care.
The anorectal unit
The anorectal unit is the hospital’s strongest draw. It is built on Gu’s Surgery, which the report said has been listed as a national heritage skill, and it sees more than 70,000 outpatient visits and over 3,000 operations a year. Dr Yao Yibo, its head, said the doctors had trained at places such as the Cleveland Clinic and the Mayo Clinic and drew on a 160-year surgical line. Its low-trauma TCM methods, he said, bring “less pain, smaller wounds, and faster recovery”.
The unit’s headline claims are clinical and financial. For Crohn’s disease with anal fistulas, the report said, its mixed protocol reaches an 88.8 per cent healing rate, against rates it put below 50 per cent abroad, and closes hard cases in about 50 days where care abroad takes three to four months. Piles treatment runs 14,000 to 15,000 yuan for insured locals and 20,000 to 30,000 yuan for foreign patients, with a full Crohn’s course near 30,000 yuan, sums the hospital said ran about ten times higher in the West. All of those numbers come from the hospital.
Shanghai is not alone in building a medical tourism case on TCM. The same draw runs through Guangzhou’s international service centre and the wider national bet on traditional Chinese medicine as an export, while China’s first foreign-owned hospital chases the same cross-border patients from a different angle.
What to watch
There is a standing way to read a hospital feature like this. The account comes from the provider, and provider numbers, healing rates, waiting times and cost gaps alike, are claims until an outside body checks them. Longhua’s Joint Commission International accreditation is the one outside marker in the piece. The 88.8 per cent healing rate, the 50-day recovery and the tenfold cost gap are the hospital’s own. Shanghai’s pilot is a statement of intent, and intent is not the same as treated volume.
The tests are countable. The number worth watching is not the healing rate but the throughput, how many foreign patients Longhua’s wards take in under the pilot, and whether other Shanghai hospitals report foreign arrivals rising as the scheme widens. Until those numbers come from somewhere other than the hospital’s own desk, the claims stay just that.
